{"id":"dose-d2-of-interleukin-2","safety":{"commonSideEffects":[{"rate":"70-80","effect":"Fever"},{"rate":"50-70","effect":"Chills"},{"rate":"60-80","effect":"Fatigue"},{"rate":"40-60","effect":"Nausea"},{"rate":"30-50","effect":"Vomiting"},{"rate":"20-40","effect":"Hypotension"},{"rate":"10-30","effect":"Capillary leak syndrome"},{"rate":"20-40","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"IL-2 is a cytokine that binds to IL-2 receptors on lymphocytes, promoting their proliferation, differentiation, and activation. This leads to enhanced cytotoxic T cell and NK cell activity against cancer cells. Dose D2 refers to a specific dosing regimen in this Phase 2 trial.","oneSentence":"Interleukin-2 activates and expands T cells and natural killer cells to enhance anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:34:32.736Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic cancer (specific indication under investigation in Phase 2)"}]},"trialDetails":[{"nctId":"NCT01862120","phase":"PHASE2","title":"Dose Finding Study of Il-2 at Ultra-low Dose in Children With Recently Diagnosed Type 1 Diabetes","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-06-27","conditions":"Type 1 Diabetes","enrollment":24},{"nctId":"NCT03778619","phase":"PHASE1, PHASE2","title":"MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin","status":"UNKNOWN","sponsor":"GC Cell Corporation","startDate":"2018-11-28","conditions":"Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma","enrollment":9}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Dose D2 of Interleukin-2","genericName":"Dose D2 of Interleukin-2","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Interleukin-2 activates and expands T cells and natural killer cells to enhance anti-tumor immune responses. Used for Advanced or metastatic cancer (specific indication under investigation in Phase 2).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}